Murcko, Mark

Mark A. Murcko, Recent Advances in Ligand Design Methods. 

Thanks go to Paul Anderson, Frank Ascione, Jerome Bimbaum, Lewis Cantley, Jennifer Darnell, Robert Darnell, Bink Garrison, Lori Morton, Mark Murcko, Larry Stemson, and Leslie Vosshall. I am also indebted to Bonnie Bassler, Milos Novotny, and Charles Wysocki who provided reprints and preprints of manuscripts covering important work cited in this book. Aspects of the structure of chapters 3-6 derive in part from a general chemistry textbook that I coauthored with Riley Schaeffer many years ago and thanks are due to Riley for his contributions. 

Dr. Renee Arnold (ACT LLC, USA) Dr. David D. Christ (SNC Partners LLC, USA) Dr. Michael J. Curtis (Rayne Institute, St Thomas Hospital, UK) Dr. James H. Harwood (Pfizer, USA) Dr. Dale Johnson (Emiliem, USA) Dr. Mark Murcko, (Vertex, USA) Dr. Peter W. Swaan (University of Maryland, USA) Dr. David Wild (Indiana University, USA) Prof. William Welsh (Robert Wood Johnson Medical School University of Medicine Dentistry of New Jersey, USA) Prof. Tsuguchika Kaminuma (Tokyo Medical and Dental University, Japan) Dr. Maggie A.Z. Hupcey (PA Consulting, USA) Dr. Ana Szarfman (FDA, USA)... 

Critical reading of this manuscript by Klaus Gundertofte and my Vertex colleagues Mark Murcko, Paul Charifson, and Brian Goldman has helped improve this manuscript considerably. Hugo Kubinyi has also provided helpful input. Norman Laurin of the Vertex Library has been invaluable in assisting with the electronic literature searching and document retrieval. 

I think that most drugs will come out of smaller organizations, says Dr Mark Murcko. I agree with the sentiment that smaller, more focused organizations are more likely to... 

But as with drugs, for each of these success stories there are probably hundreds more that just never worked out. As Chief Technology Officer at Vertex Pharmaceuticals, Dr Mark Murcko has been asked to evaluate quite a few new technology proposals. What typically happens, he says, is that if it works great on the first test case, some people will naively... 

Most scientists whose careers haven t yet spanned such a complete cycle tend to think it s on the order of a few years. Among those with a longer perspective, estimates are larger but still diverge a bit. According to Dr Mark Murcko, it varies of course, but I think it s often as much as a decade before the pharmaceutical industry can gain widespread value from new... 

Dr Mark Murcko of Vertex Pharmaceuticals provides an example of how this might work for a real-world project In the area of kinases or ion channels or GPCRs we ve already worked on other members of the family, he notes. We already have some know-how about how to set up an assay in the field. We may already have useful compounds—not drug candidates, perhaps—but pretty decent starting points. Let s say we read a paper in Nature that suggests that kinase X is a great target for cancer. But it s speculative. 

Dr Mark Murcko, Chief Technology Officer, Vertex Pharmaceuticals... 

Dr Mark Murcko, quoted in Clough, J. Mark Murcko discusses enabling technologies in drug discovery. Drug Discov. Today Biosilico 2004, 2, 51-54. 

In Chapter 1, Dr. Mark Murcko gives a detailed exposition ligand design. To appreciate the meaning of de novo, the term should be contrasted with traditional medicinal chemistry, which starts with a lead compound. The lead compound is usually a bioactive chemical that has... 

Mark A. Murcko, Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, Massachusetts 02139-4242, U.S.A. (Electronic mail markrn vpharm.com)... 

George W. A. Milne Gerd Moeckel Pierre-Yves Morgantini Keiji Morokuma Morton E. Munk Mark A. Murcko Robert B. Murphy Jane S. Murray Shinichiro Nakamura... 

---